Daniel Siudela, RPH | |
2302 Sheffield Rd, Aliquippa, PA 15001-2302 | |
(724) 375-5558 | |
(724) 857-3080 |
Full Name | Daniel Siudela |
---|---|
Gender | Male |
Speciality | Pharmacist |
Location | 2302 Sheffield Rd, Aliquippa, Pennsylvania |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1770800427 | NPI | - | NPPES |
RP034272L | Other | PA | STATE LICENSE |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
183500000X | Pharmacist | RP034272L (Pennsylvania) | Primary |
Mailing Address | Practice Location Address |
---|---|
Daniel Siudela, RPH 211 Valleyview Dr, Mc Donald, PA 15057-2620 Ph: (412) 257-3007 | Daniel Siudela, RPH 2302 Sheffield Rd, Aliquippa, PA 15001-2302 Ph: (724) 375-5558 |
News Archive
AvidBiotics today announced the receipt of two new grants totaling $1 million dollars from the National Institutes of Health that further the development of the company's novel Avidocin™ platform for narrow spectrum antibacterial proteins against important health care threats. These grants add to three previous grants covering AvidBiotics' anti-infectious disease technologies, which provide approximately $3.4 million in currently active funding for the company.
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has held its second meeting with the Australian Therapeutic Goods Administration ("TGA") to discuss milestones for approval of PV-10 for treatment of metastatic melanoma. The TGA is the part of the Australian Government's Department of Health and Ageing responsible for the assessment, approval and monitoring of therapeutic goods available in Australia. The initial meeting with the TGA was held in October 2008.
The Illinois chapters of the American College of Surgeons (ACS), Blue Cross and Blue Shield of Illinois (BCBSIL), and Northwestern Medicine- have come together to offer selected hospitals across Illinois the opportunity to join the Illinois Surgical Quality Improvement Collaborative (ISQIC), a three-year effort to improve the safety and quality of surgical care in Illinois.
The US Food and Drug Administration (FDA) approved Tekamlo™ (aliskiren and amlodipine) tablets, a single-pill for the treatment of high blood pressure combining the only approved direct renin inhibitor, Tekturna® (aliskiren), with the widely used calcium channel blocker amlodipine. Tekamlo is approved as initial therapy for patients who are likely to need multiple drugs to achieve their blood pressure goals, and as replacement therapy for patients whose blood pressure is not adequately controlled with either aliskiren or amlodipine alone.
The CHIME Foundation, which represents more than 1,400 of the healthcare industry's leading Chief Information Officers, named Glen Tullman, Chief Executive Officer of Allscripts, the 2011 winner of its Lifetime Achievement Award.
› Verified 2 days ago
Mrs. Antoniette Barbuto, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2665 Brodhead Rd, Suite B, Aliquippa, PA 15001 Phone: 724-375-1230 | |
Lori Zelesnik, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 143 Turkmar Dr, Aliquippa, PA 15001 Phone: 724-775-5325 | |
Adam Andrew, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2003 Sheffield Rd, Aliquippa, PA 15001 Phone: 180-085-0339 | |
Mrs. Heather Walsh, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2665 Brodhead Rd, Aliquippa, PA 15001 Phone: 724-378-4141 | |
Mr. Gino S. Cordisco, R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2003 Sheffield Rd, Aliquippa, PA 15001 Phone: 724-816-2512 Fax: 724-776-7237 | |
Douglas Kaleugher, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2003 Sheffield Rd, Aliquippa, PA 15001 Phone: 724-378-5325 Fax: 724-378-5312 | |
James Conrad Burke, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2003 Sheffield Rd, Suite B, Aliquippa, PA 15001 Phone: 724-375-1672 |